Biotest Pharma Gmbh

Association Pour L'essor De La Transfusion Sanguine Dans La Region Du

Michael Kloft

Dieter Rudnick

Norbert Kothe

Ulf Bethke

Detlef Rohm

Dominique Bourel

Wolfgang Stephan

Roland Beliard

Wolfgang Moller

Herbert Dichtelmuller

Detlef Piechaczek

Herwald Klein

Magali Holuigue

Peter Byrne

Herve Broly

Ahmed Bouzidi

The invention relates to the fractionation of plasma or serum into at least one albumin fraction and one immunoglobulin fraction by hydrophobic interaction chromatography. The fractionation is carried out using an incremental salt gradient, especially an ammonium sulfate buffer. The invention also relates to preparations obtained by using said method and to their use.

Method for the chromatographic fractionation of plasma or serum, preparations, so obtained, and their use

The invention relates to 2 human monoclonal antibodies of sub-classes IgG1 and IgG3, against the Rhesus D antigen and to a pharmaceutical composition containing a mixture of the said antibodies, more particularly intended for the prophylaxis of the haemolytic disease of the newborn. The invention also relates to the heterohybridoma cell lines that produce these antibodies, which are filed with the 'Deutsche Sammlung von Mikroorganismen und Zellkulturen' under accession numbers DSM AC 2039 and DSM AC 2040.

Human monoclonal anti-rhesus (D) antibodies and cell lines producing same

Method of manufacturing an intravenously tolerable immunoglobulin-G preparation that is free of aggregates, vasoactive substances and proteolytic enzymes and accordingly appropriate for all types of patients, especially immunosuppressed patients, from a starting material that contains immunoglobulin G but from which the coagulation factors have been removed. The starting material is treated with 0.4 to 1.5% by volume of octanoic acid and then chromatographed, especially on an ion or cation exchanger or hydrophobic matrix.

Manufacturing intravenous tolerable immunoglobulin-G preparation

To provide a simple method of preparing biologically active transferrin that can be employed on an industrial scale and that will result in extremely pure and natural transferrin containing no viruses and appropriate for both in-vitro and in-vivo applications, the .gamma.-globulins are precipitated from the fraction containing the transferrin, the precipitant is removed from the residual liquid by ultrafiltration or gel filtration, the liquid is adjusted to a prescribed ionic concentration and protein concentration and (a) treated with .beta.-propiolactone and the solution is subjected to ultraviolet radiation or (b) treated with specific detergents and subjected to ion-exchange chromatography, and the transferrin is concentrated and filtered sterile.

Method of preparing a high-purity, virus safe, biologically active

The present invention involves a polyvalent hyperimmunoglobulin preparation having activity against gram negative and gram positive bacteria. Such a polyvalent hyperimmunoglobulin preparation is prepared from plasma, serum or whole blood from donors. Donor selection is based upon titer against E. coli J5 antigen or against lipid A antigen.

Polyvalent hyperimmunoglobulin preparation

Growing community of inventors

Darmstadt, Germany

Michael Kloft